首页> 中国专利> 一种感应爆炸物分子的Arac突变体AraCmt1及其筛选方法和应用

一种感应爆炸物分子的Arac突变体AraCmt1及其筛选方法和应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明公开了一种感应爆炸物分子的Arac突变体AraCmt1及其筛选方法和应用。所述Arac突变体AraCmt1的氨基酸序列如SEQ ID NO.13所示，所述Arac突变体AraCmt1的编码基因的核苷酸序列如SEQ ID NO.12所示，或者与SEQ ID NO.12所示的核苷酸序列具有95%以上同源性的且能编码如SEQ ID NO.13所示的氨基酸序列的核苷酸序列。所述的突变体AraCmt1能够特异性结合爆炸物分子2,4‑二硝基甲苯（2,4‑DNT），并受其诱导而激活PBAD启动子，从而表达下游报告基因，进而通过荧光强度或者颜色反应检测微量的2,4‑DNT，因此适用于制备感应2,4‑DNT的微生物传感器。

著录项

公开/公告号CN113527460A

专利类型发明专利
公开/公告日2021-10-22

原文格式PDF
申请/专利权人青岛农业大学;
展开▼

申请/专利号CN202110755119.X
发明设计人杨建明;李美洁;吕书喆;汤若昊;梁波;王兆宝;
展开▼

申请日2021-07-05
分类号C07K14/47(20060101);C12N15/12(20060101);C12N15/70(20060101);C12N1/21(20060101);G01N33/68(20060101);C12R1/19(20060101);
代理机构37264 青岛合创知识产权代理事务所(普通合伙);
代理人王晓晓
地址 266000 山东省青岛市城阳区长城路700号
入库时间 2023-06-19 12:59:17

法律信息

法律状态公告日

法律状态信息

法律状态
2023-06-20

授权

发明专利权授予

相似文献

专利
中文文献
外文文献

1. 一种感应爆炸物分子的Arac突变体AraCmt1及其筛选方法和应用 [P] . 中国专利： CN113527460A . 2021-10-22
2. 一种AraC突变体蛋白及其应用 [P] . 中国专利： CN103626852B . 2016.02.24
3. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
4. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
5. Soluble CTLA4 Mutant Molecule; fusion protein ctla4ig soluble CD86 Antigen reactive with the Mutant receptor protein and soluble CTLA4 Mutant that include encoding acid Molecule;Nucleic and cDNA expressing Plasmid which includes; The latter method to produce; [P] . AR007225A1 . 1999-10-27

机译：可溶性CTLA4突变分子;融合蛋白ctla4ig可溶性CD86与突变体受体蛋白和可溶性CTLA4突变体反应的抗原，包括编码酸性分子;核酸和cDNA表达质粒，包括：后一种方法产生;